Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine
Public ClinicalTrials.gov record NCT04707391. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIIB, Randomized, Controlled, Observer-blind Study to Evaluate Safety and Immunogenicity of GSK's Meningococcal ABCWY Vaccine When Administered in Healthy Adolescents and Adults, Previously Primed With Meningococcal ACWY Vaccine
Study identification
- NCT ID
- NCT04707391
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 1,250 participants
Conditions and interventions
Conditions
Interventions
- MenABCWY vaccine Combination Product
- Placebo Combination Product
- MenACWY vaccine Biological
- MenB vaccine Combination Product
Combination Product · Biological
Eligibility (public fields only)
- Age range
- 15 Years to 25 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 24, 2021
- Primary completion
- May 2, 2023
- Completion
- Sep 28, 2023
- Last update posted
- Jul 2, 2024
2021 – 2023
United States locations
- U.S. sites
- 48
- U.S. states
- 20
- U.S. cities
- 45
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Jonesboro | Arkansas | 72401 | — |
| GSK Investigational Site | Banning | California | 92220 | — |
| GSK Investigational Site | Chula Vista | California | 91911 | — |
| GSK Investigational Site | West Covina | California | 91790 | — |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20017 | — |
| GSK Investigational Site | Miami | Florida | 33126 | — |
| GSK Investigational Site | Miami | Florida | 33135 | — |
| GSK Investigational Site | Port Orange | Florida | 32127 | — |
| GSK Investigational Site | Atlanta | Georgia | 30338 | — |
| GSK Investigational Site | Columbus | Georgia | 31904 | — |
| GSK Investigational Site | Sandy Springs | Georgia | 30328 | — |
| GSK Investigational Site | Meridian | Idaho | 83642 | — |
| GSK Investigational Site | Champaign | Illinois | 61822 | — |
| GSK Investigational Site | Quincy | Illinois | 62301 | — |
| GSK Investigational Site | Louisville | Kentucky | 40291 | — |
| GSK Investigational Site | Boston | Massachusetts | 02114 | — |
| GSK Investigational Site | Fall River | Massachusetts | 02725 | — |
| GSK Investigational Site | Methuen | Massachusetts | 01844 | — |
| GSK Investigational Site | Roslindale | Massachusetts | 02135 | — |
| GSK Investigational Site | Grosse Pointe Woods | Michigan | 48236 | — |
| GSK Investigational Site | Biloxi | Mississippi | 39531 | — |
| GSK Investigational Site | Albuquerque | New Mexico | 87102 | — |
| GSK Investigational Site | Syracuse | New York | 13210 | — |
| GSK Investigational Site | Fayetteville | North Carolina | 28304 | — |
| GSK Investigational Site | Raleigh | North Carolina | 27612 | — |
| GSK Investigational Site | Wilmington | North Carolina | 28401 | — |
| GSK Investigational Site | Cranberry Township | Pennsylvania | 16066 | — |
| GSK Investigational Site | Monongahela | Pennsylvania | 15063 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15025 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15213 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15217 | — |
| GSK Investigational Site | Warwick | Rhode Island | 02886-6110 | — |
| GSK Investigational Site | Charleston | South Carolina | 29406 | — |
| GSK Investigational Site | Greenville | South Carolina | 29607 | — |
| GSK Investigational Site | Austin | Texas | 78745 | — |
| GSK Investigational Site | Beaumont | Texas | 77706 | — |
| GSK Investigational Site | Carrollton | Texas | 75010 | — |
| GSK Investigational Site | Dallas | Texas | 75251 | — |
| GSK Investigational Site | Houston | Texas | 77055 | — |
| GSK Investigational Site | Katy | Texas | 77450 | — |
| GSK Investigational Site | Longview | Texas | 75605 | — |
| GSK Investigational Site | Plano | Texas | 75024 | — |
| GSK Investigational Site | The Woodlands | Texas | 77381-3527 | — |
| GSK Investigational Site | Kaysville | Utah | 84037 | — |
| GSK Investigational Site | Layton | Utah | 84041 | — |
| GSK Investigational Site | Roy | Utah | 84067 | — |
| GSK Investigational Site | Syracuse | Utah | 84075 | — |
| GSK Investigational Site | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04707391, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 2, 2024 · Synced Jul 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04707391 live on ClinicalTrials.gov.